Search results
25 kwi 2021 · For apixaban, efficacy and safety were broadly similar between the NOAC and LMWH. Concerning the prevention of stroke and systemic embolism in AF patients with cancer, available evidence is less strong, as active malignancy was an exclusion criterion in most NOAC AF Phase III trials.
The 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation: Full Guide (pdf) / in EP Europace 2021 Key Message (exclusive content for EHRA Members)
19 kwi 2022 · Praktyczny przewodnik EHRA 2021 dotyczący stosowania doustnych leków przeciwkrzepliwych niebędących antagonistami witaminy K u pacjentów z migotaniem przedsionków. Rok publikacji wytycznych: 2021. Data publikacji na portalu: 2022-04-19. Problem: migotanie przedsionków, leczenie przeciwkrzepliwe.
9 paź 2021 · 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace. 2021 Oct 9;23 (10):1612-1676. doi: 10.1093/europace/euab065. Authors.
2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Table of contents. NOAC eligibility and dosing
• Risk/benefit analysis: is a NOAC indicated? • When choosing a NOAC, consider co-medications taken by patient. • Consider co-medications such as PPI to reduce risk for gastro-intestinal bleeding. • Carry information card: generic card could serve for all NOACs. • Need to educate patient on importance of strict adherence to
4 wrz 2021 · 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: comment. Joshua Mbroh. , Sven Poli. EP Europace, Volume 23, Issue 10, October 2021, Page 1685, https://doi.org/10.1093/europace/euab217. Published: 04 September 2021. PDF. Split View. Cite.
